Clinical characteristics and current therapies for inherited retinal degenerations

Inherited retinal degenerations (IRDs) encompass a large group of clinically and genetically heterogeneous diseases that affect approximately 1 in 3000 people (>2 million people worldwide) (Bessant DA, Ali RR, Bhattacharya SS. 2001. Molecular genetics and prospects for therapy of the inherited re...

Full description

Saved in:
Bibliographic Details
Published in:Cold Spring Harbor perspectives in medicine 2015-02, Vol.5 (2), p.a017111-a017111
Main Authors: Sahel, José-Alain, Marazova, Katia, Audo, Isabelle
Format: Article
Language:English
Subjects:
Animals
Bardet-Biedl Syndrome - genetics
Choroideremia - genetics
Clinical Trials as Topic
Color Vision Defects - genetics
Disease Models, Animal
Eye Diseases, Hereditary - genetics
Genetic Diseases, X-Linked - genetics
Genetic Heterogeneity
Genetic Therapy
Humans
Leber Congenital Amaurosis - genetics
Macular Degeneration - genetics
Myopia - genetics
Night Blindness - genetics
Optogenetics
Retinal Degeneration - genetics
Retinal Degeneration - pathology
Retinal Degeneration - therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inherited retinal degenerations (IRDs) encompass a large group of clinically and genetically heterogeneous diseases that affect approximately 1 in 3000 people (>2 million people worldwide) (Bessant DA, Ali RR, Bhattacharya SS. 2001. Molecular genetics and prospects for therapy of the inherited retinal dystrophies. Curr Opin Genet Dev 11: 307-316.). IRDs may be inherited as Mendelian traits or through mitochondrial DNA, and may affect the entire retina (e.g., rod-cone dystrophy, also known as retinitis pigmentosa, cone dystrophy, cone-rod dystrophy, choroideremia, Usher syndrome, and Bardet-Bidel syndrome) or be restricted to the macula (e.g., Stargardt disease, Best disease, and Sorsby fundus dystrophy), ultimately leading to blindness. IRDs are a major cause of severe vision loss, with profound impact on patients and society. Although IRDs remain untreatable today, significant progress toward therapeutic strategies for IRDs has marked the past two decades. This progress has been based on better understanding of the pathophysiological pathways of these diseases and on technological advances.
ISSN:2157-1422
2157-1422
2472-5412
DOI:10.1101/cshperspect.a017111